Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1066 | 1145 | 1180 | 1165 | 1637 | 2468 |
Fund Return | 6.56% | 14.54% | 18% | 5.22% | 10.36% | 9.45% |
Place in category | 149 | 122 | 71 | 145 | 37 | 47 |
% in Category | 15 | 12 | 7 | 29 | 9 | 13 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Janus Balanced Fund A USD Acc | 7.37B | 4.55 | 4.28 | 6.43 | ||
Janus Balanced Fund I USD Acc | 7.37B | 4.71 | 5.35 | 7.48 | ||
Janus Global Life Sciences Fund A U | 3.91B | 6.41 | 4.36 | 8.61 | ||
Janus Global Technology Fund A USD | 436.99M | 13.28 | 6.37 | 15.90 | ||
Janus Global Technology Fund I USD | 436.99M | 13.46 | 7.26 | 16.87 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Janus Global Life Sciences Fund A U | 3.91B | 6.41 | 4.36 | 8.61 | ||
Wellington Global Health Care EquiD | 2.5B | 4.11 | -0.10 | 7.92 | ||
Wellington Global Health Care EquiS | 2.5B | 4.22 | 0.55 | 8.62 | ||
Wellington Global Health Care EquUG | 2.5B | 0.58 | -0.92 | 9.63 | ||
Wellington Global Health Care EquiN | 2.5B | 0.54 | -1.41 | 9.08 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Eli Lilly | US5324571083 | 6.66 | 735.54 | -2.69% | |
UnitedHealth | US91324P1021 | 5.99 | 492.66 | -0.06% | |
Novo Nordisk B | DK0062498333 | 4.82 | 850.6 | -2.58% | |
Merck&Co | US58933Y1055 | 3.57 | 127.52 | -0.58% | |
AstraZeneca | GB0009895292 | 3.57 | 12,050.0 | -0.87% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Strong Buy |
Technical Indicators | Strong Buy | BUY | Strong Buy |
Summary | Strong Buy | Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review